Eli Lilly and Company
893 S Delaware St
Indianapolis
Indiana
46285
United States
2654 articles with Eli Lilly and Company
-
Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata
10/30/2020
Data support baricitinib's ongoing Phase 3 program and potential to be the first approved medicine for people living with alopecia areata (AA)
-
New Data at EADV 2020 Confirm Taltz® (ixekizumab) Demonstrates Sustained Long-Term Efficacy in Patients with Psoriasis and Psoriatic Arthritis
10/29/2020
Eli Lilly and Company (NYSE: LLY) announced today it will share new Taltz® (ixekizumab) data from multiple long-term and post-hoc analyses that indicate sustained efficacy in patients with psoriasis and psoriatic arthritis.
-
Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19
10/28/2020
Eli Lilly and Company announced an initial agreement with the U.S. government to supply 300,000 vials of bamlanivimab 700 mg, an investigational neutralizing antibody, for $375 million.
-
Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine
10/28/2020
The New England Journal of Medicine has published data from the monotherapy arms of BLAZE-1, a Phase 2 study assessing the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) bamlanivimab (LY-CoV555) – a neutralizing antibody – in the COVID-19 outpatient setting. This study focused on ambulatory COVID-19 patients being treat
-
Lilly Reports Third-Quarter Financial Results, Updates Guidance
10/27/2020
Revenue in the third quarter of 2020 increased 5 percent driven by volume growth of 9 percent, while on a year-to-date basis revenue increased 6 percent driven by volume growth of 12 percent.
-
Eli Lilly is continuing their other trial in mild-to-moderate COVID-19 patients and stated they “remain confident … that bamlanivimab monotherapy may prevent progression of disease for those earlier in the course of COVID-19.”
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.
-
Lilly Declares Fourth-Quarter 2020 Dividend
10/19/2020
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2020 of $0.74 per share on outstanding common stock.
-
UCB Snags Eli Lilly U.K. Research Site, Plans to Invest £1 Billion Over Five Years for R&D
10/16/2020
UCB is investing more than £1 billion over five years to expand its research and development capabilities in the U.K., which will include a transition to a newly acquired 47-acre R&D campus from Eli Lilly located in Windlesham, Surrey. -
Lilly Announces Agreement to Acquire Disarm Therapeutics
10/15/2020
Acquisition expands Lilly's R&D efforts in pain and neurodegeneration with the addition of Disarm's promising preclinical SARM1 programs for axonal degeneration [15-October-2020] INDIANAPOLIS and CAMBRIDGE, Mass. , Oct. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a definitive agreement to acquire Disarm Therapeutics, a privately-he
-
Several biopharmaceutical companies have made headway as of late in the race to develop a vaccine for COVID-19, which is responsible for the current global pandemic.
-
Eli Lilly is betting on a new approach to axonal degeneration, announcing a definitive agreement to acquire Disarm Therapeutics, a privately-held biotech company committed to solving this mystery.
-
Glitches in the COVID-19 Race: Less than 24 Hours After J&J Pauses Vaccine Trial, Eli Lilly Pause...
10/13/2020
Eli Lilly announced that it is pausing its clinical trial of a combination antibody against COVID-19 over safety concerns. Typically, this would be because a patient or volunteer showed a serious side effect or became sick, but the company did not clarify what the reason for the pause is. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.
-
Mirikizumab Shows Continued Symptom Improvement and Reduction of Intestinal Inflammation in Patients with Crohn's Disease in 52-Week Phase 2 Trial
10/12/2020
Results from the 52-week study showed continued symptom improvement and reduction of intestinal mucosal inflammation in patients with moderately to severely active Crohn's disease
-
Innovent and Lilly expect Halpryza to be a high quality and slightly more affordable rituximab injection for a market experiencing serious needs.
-
Clinical Catch-Up: October 5-9
10/12/2020
It was a moderately busy week for clinical trial news. Here’s a look. -
Lilly's OVERCOME Study Reveals Nearly 80% of People Reported Improvement in Their Migraine Since Starting a CGRP Monoclonal Antibody for Preventive Treatment
10/9/2020
Largest Real-World Study of Patient-Reported Outcomes in People with Migraine Shows the Use of Novel CGRP Monoclonal Antibody Class May Improve Migraine
-
Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA® (Rituximab Injection) in China
10/9/2020
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Eli Lilly and Company ("Lilly", NYSE: LLY),
-
Lilly Announces Arrangement for Supply of Potential COVID-19 Antibody Therapy for Low- and Middle-Income Countries
10/8/2020
Eli Lilly and Company and the Bill & Melinda Gates Foundation, as part of the COVID-19 Therapeutics Accelerator, have entered into an agreement to facilitate access to future Lilly therapeutic antibodies under development for the prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus, to benefit low- and middle-income countries.